Proposed amendments to New Drugs and Clinical Trial Rules will scrap test licences, cut application processing time. Move part of govt effort to establish India as hub for pharma R&D.
Analysts from AllianceBernstein point to four areas where India lags behind its Asian peers and underline that nation finds no mention in global healthcare innovation index.
Production of PenG, used to treat tetanus, strep infections, syphilis, pneumonia & more, was stopped in India in 1990s after cheaper alternatives began surfacing in global market.
Under revised good manufacturing practices (GMP) norms, pharma companies will be required to assume onus for quality of drugs to ensure they do not place patients at risk.
India is the world's third largest maker of drugs by volume, and US sales, which account for 30% of total pharma exports, have risen by 6.2% last year.
After an inspection, the Haryana government finds 12 flaws in the manufacturing facility; ‘Action will be taken,’ says Home and Health Minister Anil Vij.
In July, alarm was raised in Gambia after several children began falling ill with kidney problems. WHO has issued an alert asking regulators to remove the company's goods from the market.
Walgreens Boots Alliance’s negotiations with Apollo and Reliance currently have the most momentum, said people in the know. Their proposal values Boots at more than £5 billion ($6.3 billion).
Conor Fahy of govt agency Enterprise Ireland says such collaboration can ‘deepen FDI’. DU V-C Yogesh Singh says MoU with Irish varsities likely by end of 2022.
Advice comes at a time when India accounts for a 5th of global generic drug supply & 40% of generics used in US. However, this strength in finished formulations relies on imported ingredients.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS